STOCK TITAN
  1. Home
  2. Sec-filings
  3. ETON
  4. [144/A] Eton Pharmaceuticals, Inc. SEC Filing

Eton Pharma (ETON) insider to sell more stock after $3.8M sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144/A

Rhea-AI Filing Summary

Eton Pharmaceuticals, Inc. (ETON) is the issuer of common stock that Sean E. Brynjelsen plans to sell under Rule 144. The notice lists a proposed sale of 100,000 common shares through Raymond James & Associates and discloses that 120,000 shares of common stock were sold on 05/28/2026 for about $3,826,015.00. The securities to be sold trace back to 1,000,000 founder shares acquired on 05/17/2017.

Positive

  • None.

Negative

  • None.
Proposed shares to be sold 100000 shares Common stock proposed for sale through Raymond James & Associates under Rule 144
Aggregate market value of proposed sale 6343000.00 Aggregate value associated with the 100,000 common shares listed for sale
Shares sold in past 3 months 120000 shares Common stock sold by Sean Brynjelsen on 05/28/2026
Aggregate value of recent sale 3826015.00 Aggregate amount for 120,000 common shares sold on 05/28/2026
Founder shares acquired 1000000 shares Founder shares of common stock acquired from issuer on 05/17/2017
Rule 144 holding period end date 08/19/2026 Date associated with the Rule 144 securities information entry
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
founder shares financial
"Common | 05/17/2017 | founder shares | Issuer"
Founder shares are the ownership stakes given to the people who start a company, often with extra voting power or protections compared with ordinary shares. For investors, they matter because founders’ control and incentives influence decisions about strategy, hiring, and whether the company sells or stays independent — like a family that keeps majority voting rights in a household decision. High founder ownership can mean stable leadership but also a risk that outside shareholders have less influence.
attorney-in-fact regulatory
"as attorney-in-fact for Sean E Brynjelsen"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the Form 144/A filing mean for ETON shareholders?
It reports that Sean E. Brynjelsen intends to sell 100,000 shares of Eton Pharmaceuticals, Inc. (ETON) common stock under Rule 144, and that he sold 120,000 shares on 05/28/2026 for about $3,826,015.00. It is a disclosure of potential and recent insider sales.

How many ETON shares are proposed to be sold under this Form 144/A?
The notice identifies a proposed sale of 100,000 shares of Eton Pharmaceuticals, Inc. common stock, to be handled through Raymond James & Associates as broker.

What ETON insider sold shares recently and how many?
The person identified is Sean E. Brynjelsen. During the past three months, he sold 120,000 shares of Eton Pharmaceuticals, Inc. common stock on 05/28/2026 for an aggregate amount of about $3,826,015.00.

What are the founder shares referenced in the ETON Form 144/A?
The securities to be sold are linked to founder shares of Eton Pharmaceuticals, Inc. common stock. The notice states that 1,000,000 such shares were acquired on 05/17/2017 from the issuer.

Who is acting on behalf of Sean E. Brynjelsen in the ETON Rule 144 sale?
The notice is signed by Rashida Mitchell, described as a duly authorized representative of Raymond James & Associates, Inc., acting as attorney-in-fact for Sean E. Brynjelsen in connection with the planned Rule 144 sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144/A: Filer Information

144/A: Issuer Information

144/A: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

144/A: Remarks and Signature

Source: View Original Filing on SEC EDGAR